phrykt

Microbot Medical Inc. (MBOT): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of MBOT were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Microbot Medical

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MBOT

72 funds and institutions reported MBOT shares worth $22.2M at the end of Q2 2026, about 17% of the company. The largest holder is Vanguard Capital Management LLC with 4.3%.

Funds and institutions (13F) 17%Everyone else 83%

10 largest owners, by share of the company

Vanguard Capital Management LLC4.3%
Mitsubishi UFJ Asset Management Co., Ltd.1.9%
BlackRock, Inc.1.3%
Geode Capital Management, LLC1.2%
UBS Group AG1.2%
DNB Asset Management AS1.0%
Stifel Financial Corp0.9%
Marshall Wace, LLP0.8%
Susquehanna International Group, LLP0.8%
Vanguard Fiduciary Trust Co0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC2.91M4.33%$5.7M-0%
Mitsubishi UFJ Asset Management Co., Ltd.1.27M1.89%$2.5MNew
BlackRock, Inc.902,4111.34%$1.8M+5%
Geode Capital Management, LLC836,2711.25%$1.6M+10%
UBS Group AG806,8471.20%$1.6M-1%
DNB Asset Management AS677,4981.01%$1.3MNo change
Stifel Financial Corp589,9240.88%$1.2M+3%
Marshall Wace, LLP541,9630.81%$1.1M+13%
Susquehanna International Group, LLP525,8270.78%$1M-43%
Vanguard Fiduciary Trust Co431,0330.64%$841K+8%
State Street Corp303,5690.45%$592KNo change
AlphaCentric Advisors LLC250,0000.37%$488K+25%
Northern Trust Corp147,5300.22%$288K+3%
Group One Trading LLC106,4290.16%$208K+129%
Jane Street Group, LLC106,1340.16%$207K-25%
American Century Companies Inc93,3140.14%$182K+651%
Millennium Management LLC86,3020.13%$168K-81%
Invesco Ltd.52,2010.08%$102K+77%
Charles Schwab Investment Management Inc50,0000.07%$97.5KNo change
Sixth Street Partners Management Company, L.P.50,0000.07%$97.5KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No MBOT insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MBOT short interest

Moderate short interest. 9.4% of MBOT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 18%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.32M MBOT shares were sold short, 9.4% of the shares outstanding, up 5.6% from the report before. At the average daily volume of 815,260 shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

9.42%May 15Oct 3011.8%

Days to cover

7.8May 15Oct 3020.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.32M9.42%+6%815,2607.8
Oct 15, 20265.99M8.92%-10%911,3566.6
Sep 30, 20266.64M9.88%-6%551,47112.0
Sep 15, 20267.07M10.53%-2%389,53218.2
Aug 31, 20267.23M10.77%+1%715,21910.1
Aug 14, 20267.19M10.70%-3%884,7798.1
Jul 31, 20267.39M11.01%-1%538,47613.7
Jul 15, 20267.49M11.15%+2%687,13710.9
Jun 30, 20267.35M10.94%-2%855,7808.6
Jun 15, 20267.49M11.15%-2%978,8477.7
May 29, 20267.64M11.38%-1%2.16M3.5
May 15, 20267.68M11.43%-0%1.99M3.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Microbot Medical company events

Microbot Medical filed 38 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementThe Company holds 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America. Filing
  2. Oct 27, 2026AnnouncementShared information with investors. Filing
  3. Oct 23, 2026AnnouncementShared information with investors. Filing
  4. Oct 20, 2026VoteSet dates for shareholder nominations. Filing
  5. Oct 6, 2026AnnouncementShared information with investors. Filing
  6. Sep 28, 2026AnnouncementShared information with investors. Filing
  7. Aug 11, 2026AnnouncementShared information with investors. Filing
  8. Aug 7, 2026LeadershipBelow is incorporated herein by reference into this Item 1.01. Filing
  9. Jul 21, 2026AnnouncementShared information with investors. Filing
  10. Jul 7, 2026AnnouncementIs hereby incorporated by reference into this Item 7.01. Filing
  11. Jun 30, 2026AnnouncementIs hereby incorporated by reference into this Item 7.01. Filing
  12. Jun 25, 2026AnnouncementShared information with investors. Filing
  13. Jun 23, 2026AnnouncementIs hereby incorporated by reference into this Item 7.01. Filing
  14. Jun 16, 2026AnnouncementShared information with investors. Filing
  15. Jun 9, 2026AnnouncementIs hereby incorporated by reference into this Item 7.01. Filing
  16. Jun 2, 2026AnnouncementThe Company announced that it has secured its first North Carolina-based customer for the LIBERTY ® Endovascular Robotic System, demonstrating a broadening geographic penetration from the southeast, mid-Atlantic and northeast U.S. Forward Looking Statements This Item 8.01 of this Current Report on… Filing
  17. May 26, 2026AnnouncementThe Company announced that it received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, which allows the Company to market and commercialize the LIBERTY ® Endovascular Robotic System in Israel, and also… Filing
  18. May 15, 2026AnnouncementShared information with investors. Filing
  19. May 14, 2026AnnouncementThe Company announced that it recorded revenue resulting from its limited market release of the LIBERTY ® Endovascular Robotic System during the first quarter of 2026, and that the Company’s recent transition to the full market release has resulted in increased revenue for the second quarter of… Filing
  20. May 5, 2026AnnouncementShared information with investors. Filing
  21. Apr 30, 2026AnnouncementShared information with investors. Filing
  22. Apr 22, 2026AnnouncementShared information with investors. Filing
  23. Apr 14, 2026AnnouncementShared information with investors. Filing
  24. Apr 13, 2026AnnouncementThe Company announced that it has successfully executed the limited market release of LIBERTY, and will commence its full market release in the U.S. as planned at the Society of Interventional Radiology (SIR) Annual Scientific Meeting being held in Toronto, ON, Canada, from April 11-15, 2026. Filing
  25. Apr 10, 2026AnnouncementMicrobot Medical Inc. previously entered into an At the Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024, with H.C. Wainwright & Co., LLC in connection with the Company’s “at the market offering” program. Filing
  26. Mar 26, 2026AnnouncementShared information with investors. Filing
  27. Mar 24, 2026AnnouncementShared information with investors. Filing
  28. Mar 17, 2026AnnouncementShared information with investors. Filing
  29. Mar 10, 2026AnnouncementShared information with investors. Filing
  30. Mar 4, 2026AnnouncementShared information with investors. Filing
  31. Mar 3, 2026AnnouncementShared information with investors. Filing
  32. Feb 24, 2026LeadershipBelow is incorporated herein by reference into this Item 1.01. Filing
  33. Feb 24, 2026AnnouncementShared information with investors. Filing
  34. Feb 19, 2026AnnouncementShared information with investors. Filing
  35. Feb 12, 2026AnnouncementShared information with investors. Filing
  36. Feb 5, 2026AnnouncementShared information with investors. Filing
  37. Jan 12, 2026AnnouncementMicrobot Medical Inc. issued a press release reaffirming its 2025 achievements and announcing its key 2026 anticipated milestones. Filing
  38. Nov 26, 2025AnnouncementEmory University Hospital has become the first hospital in the world to adopt the Company’s LIBERTY ® Endovascular Robotic System for patient care. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Microbot Medical financials

Famous investors that hold MBOT

1 of the 50 well-known investors we track reported holding MBOT in their latest 13F filing. The largest position is Ken Griffin's, worth $437K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026363,770$437K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Microbot Medical Inc. (MBOT) stock

Who owns the most MBOT stock?

The largest reported owner of Microbot Medical Inc. (MBOT) is Vanguard Capital Management LLC, with 4.3% of the company. In total, 72 funds and institutions reported holding MBOT at the end of Q2 2026, together about 17% of the shares. See the largest owners.

Are MBOT insiders buying or selling?

No MBOT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in MBOT?

As of Oct 30, 2026, 6.32M MBOT shares were sold short, 9.4% of the shares outstanding, up 5.6% from the report before. At the average daily volume of 815,260 shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold MBOT?

1 of the 50 well-known investors we track reported MBOT in their latest 13F filing, including Ken Griffin. The largest position is worth $437K. See all holders.

Executive pay

Microbot Medical's chief executive was paid a total of $1.7M for the year ended Dec 31, 2025, up 34% from $1.2M the year before. In the last 12 months, Microbot Medical's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$523KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.